U.S. Healthcare Spending Just Climbs: 2 Stocks to Buy

Why u.s. healthcare spending just hit a new milestone—and why it matters for investors

If you’ve noticed bigger medical bills or steeper insurance premiums lately, you’re not imagining things. The overall price tag for health care in the United States has climbed to about $5.7 trillion, reflecting a sustained push higher across hospitals, drugs, devices, and services. For investors, that durability is a clue: a rising, aging population and constant medical innovation create a long runway for certain companies. That’s why we’re focused on opportunities that can ride the trend for years to come.

In plain terms, the u.s. healthcare spending just shows how essential health care is to the economy. It isn\'t a temporary spike tied to one policy or one disease. It’s a structural shift driven by demographics, technology, and evolving care practices. There are winners and losers in this space, and the smartest moves come from firms that can consistently grow earnings while expanding access or lowering total care costs for patients.

The big drivers: why spending keeps rising

Several forces are stacking the deck for healthcare spending growth over the next decade:

• Population aging: The share of seniors is swelling, and older adults typically require more care and ongoing medications.
• Chronic disease burden: Diabetes, cardiovascular disease, and obesity drive long-term drug use and medical services.
• Medical innovation: Breakthrough treatments, personalized medicine, and next-generation devices push up per-patient costs—but also improve outcomes.
• Administrative and pricing dynamics: Insurance interactions, reimbursement changes, and pricing transparency influence the overall spend curve.

Where the fastest growth is likely to come from

Not all segments rise at the same pace. Some niches accelerate as new therapies reach scale, while others lag due to funding or competitive pressure. A few areas that look particularly strong over the long run include:

• Biopharma with disease-modifying therapies: Treatments that can alter the course of chronic illnesses tend to command premium pricing and durable demand.
• Non-invasive and minimally invasive care: Robotics, imaging, and home-based care are lowering barriers to access and could expand volumes.
• Outpatient and digital health: Telehealth, wearables, and remote monitoring reduce costs and keep patients engaged in ongoing care.

In practice, this means investors should be mindful of the pace at which a company can scale its products, how it manages margins during growth, and how it navigates regulatory and competitive hurdles. The goal is to find firms that can compound earnings even as the sector grows stubbornly larger each year.

Two stocks to consider as the healthcare tailwind persists

Two names that often surface for investors seeking exposure to a long-running healthcare growth trajectory are:

• Eli Lilly (LLY): A leading biopharma with a growing portfolio of disease-modifying therapies, including prominent attention in obesity and diabetes care. Lilly’s pipeline-backed growth has historically supported revenue and earnings momentum even as the broader market cycles through slower periods.
• Intuitive Surgical (ISRG): A dominant player in robotic-assisted surgery. As hospitals pursue efficiency and patient outcomes improve, the installed base and recurring instrument revenues offer a durable growth story that isn\'t purely dependent on drug cycles or policy shifts.

Remember, these picks reflect a focus on long-term tailwinds rather than short-term catalysts. The case for each stock rests on its ability to expand addressable markets, sustain clinical or clinical-adjacent innovations, and deliver consistent cash flow growth over multiple years. This approach aligns with the idea that u.s. healthcare spending just continues to trend higher, creating steady demand for better therapies and better care experiences.

Eli Lilly (LLY): How the company could ride the GLP-1 wave

Gaining pace in the last few years, GLP-1 therapies have transformed how clinicians manage obesity and type 2 diabetes. Lilly’s portfolio—anchored by a flagship GLP-1 drug and a rapidly expanding line of obesity medications—has helped the company deliver stronger top-line growth than many peers. Investors are watching for two key signals: sustained drug demand and meaningful margins as manufacturing scales up to meet global adoption. A next-year plan that expands worldwide access and maintains competitive pricing could further lift earnings power.

From a cash-flow perspective, Lilly has the mix of product sales, strong operating leverage, and disciplined capital allocation that can translate into higher returns for shareholders over a multi-year horizon. The challenge is to balance pipeline risk with the potential upside from GLP-1 uptake and related therapies in other disease areas.

Intuitive Surgical (ISRG): The robotics-led path to more efficient care

Intuitive Surgical sits at the intersection of medicine and automation. The company’s da Vinci systems have become a standard in many operating rooms, enabling surgeons to perform complex procedures with precision. The growth case rests on a growing installed base, higher utilization rates, and a path to more affordable instruments and maintenance over time. Demand for minimally invasive procedures is broadening across specialties, which can support a steady stream of service revenue and consumables that complement device sales.

Another advantage: hospitals face capacity and staff constraints, making efficient, repeatable surgical workflows more valuable. As a result, ISRG’s mix of hardware, software upgrades, and ongoing service revenue may provide a steadier earnings trajectory even when other parts of the healthcare market face volatility.

Practical strategies to invest in a rising healthcare spend environment

If you’re thinking about how to position a portfolio for a persistently rising healthcare spend, here are practical, actionable steps:

• Pair leaders with innovators: Blend a mature, cash-generative company (like a pharmaceutical stalwart) with a growth-oriented device or tech leader to balance risk and reward.
• Consider a tiered approach: Allocate a core position in a high-conviction stock and satellite exposure to a couple of smaller-cap names with compelling pipelines or services capabilities.
• Use a patient, long-term lens: Treat healthcare stocks as multi-year holdings. Short-term volatility can be high due to policy shifts or trial results, but the long-term demand story remains intact.
• Dace with diversification: Don’t put all eggs in one basket. Add exposure to healthcare services, devices, and life sciences to spread risk across the value chain.
• Balance with hedges: A combination of traditional equities and sector-focused ETFs can dampen drawdowns while you stay exposed to the growth trend.

How to build a simple, printable framework for healthcare investing

One practical framework is to start with an allocation target and then adjust as you learn. For a long-term investor, a 10%-15% exposure to U.S. healthcare stocks (split between pharma, devices, and services) can deliver meaningful growth without overwhelming your portfolio’s risk profile.

• Step 1: Decide your time horizon (5+ years) and your risk tolerance (moderate to high).
• Step 2: Pick 2-3 core holdings with durable earnings momentum and a pair of complementary growth bets in devices or services.
• Step 3: Add a healthcare ETF or sector-specific fund for broad exposure to earnings growth, price discipline, and diversification.
• Step 4: Review quarterly results and policy developments, adjusting weights if the long-term trend looks more or less favorable.

FAQ

Q1: Why is healthcare spending rising so consistently?

A1: A combination of an aging population, higher use of medical services, and rapid medical innovation keeps driving costs higher. New treatments and devices improve outcomes but add to the overall price tag over time.

Q2: Are Lilly and ISRG good long-term bets in this trend?

A2: Both have durable growth catalysts—Lilly with its strong drug portfolio and Isrg with its leadership in robotics for surgery. They offer different risk/return profiles: Lilly is more drug-dominant and sensitive to regulatory and pricing changes, while ISRG is more asset- and service-driven with a robotics-adoption tailwind.

Q3: what other investment options can help me participate in this trend?

A3: Consider sector ETFs that focus on healthcare innovation, diversified healthcare earnings, or medical devices. You can also use mutual funds or target-date funds with a higher allocation to healthcare equities if you want professional management and diversification.

Q4: How should I handle risk in a rising-spend environment?

A4: Diversification is your friend. Keep position sizes reasonable, use stop-loss or risk-managed approaches, and avoid chasing unproven hype. Favor companies with clear competitive advantages, consistent margins, and scalable models.

Conclusion: stay invested in the healthcare growth story

The takeaway is straightforward: healthcare remains a cornerstone of the U.S. economy. The trend of rising spending, driven by demographics and innovation, creates a multi-year opportunity for investors who pick durable franchises and balance them with growth-driven names. The two stocks highlighted here—Eli Lilly and Intuitive Surgical—illustrate how different paths can both align with the overarching tailwinds. Lilly uses a powerful drug platform to grow revenue, while ISRG leverages robotics to redefine surgical care. If you adopt a thoughtful, diversified approach and stay focused on the long term, you can participate in a healthcare growth cycle that isn\'t going away anytime soon.

Frequently asked questions

For quick clarity, here are concise answers to common questions about healthcare spending and investing in this space.